



OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

**AUDITED CONSOLIDATED FINANCIAL STATEMENTS AND
SUPPLEMENTARY SCHEDULES**

FOR THE YEAR ENDED DECEMBER 31, 2024
(WITH SUMMARIZED COMPARATIVE TOTALS FOR THE YEAR ENDED DECEMBER 31, 2023)

with

INDEPENDENT AUDITORS' REPORT THEREON



OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

INDEX

	<u>Page</u>
Independent Auditors' Report	1 - 4
Consolidated Statements of Financial Position	5
Consolidated Statements of Activities	6
Consolidated Statements of Functional Expenses	7
Consolidated Statements of Cash Flows	8
Notes to Consolidated Financial Statements	9 - 19
Supplementary Schedules:	
Consolidating Schedule of Financial Position	20
Consolidating Schedule of Activities	21
Consolidating Schedule of Functional Expenses	22

Independent Auditors' Report

To the Board of Directors
Open Medicine Foundation

Opinion

We have audited the consolidated financial statements of Open Medicine Foundation and its related entities (the “Organization,” a non-profit corporation), which comprise the consolidated statements of financial position as of December 31, 2024, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, based on our audit and the report of other auditors, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Organization as of December 31, 2024, and the change in its consolidated net assets and its consolidated cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

We did not audit the financial statements of Open Medicine Foundation Canada and Open Medicine Foundation Australia, related entities, which statements reflect total assets constituting 26% and 11%, respectively, of consolidated total assets at December 31, 2024, and total revenues constituting 23% and 8%, respectively, of consolidated total revenues for the year then ended. Those statements, which were prepared in accordance with Canadian and Australian generally accepted auditing standards, respectively, were audited by other auditors, whose reports have been furnished to us. We have applied audit procedures on the conversion adjustments to the consolidated financial statements of the Organization, which conform those financial statements to accounting principles generally accepted in the United States of America. Our opinion, insofar as it relates to the amounts included for the Organization, prior to these conversion adjustments, is based solely on the reports of the other auditors.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (“GAAS”). Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Financial Statements section of our report.

We are required to be independent of the Organization, and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplementary consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, net assets, and cash flows of the individual entities and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.



Report on Summarized Comparative Information

We have previously audited the Organization's December 31, 2023 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated April 22, 2024. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2023 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

PDM, LLP

Torrance, California
May 7, 2025

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

DECEMBER 31, 2024

(WITH SUMMARIZED COMPARATIVE TOTALS FOR DECEMBER 31, 2023)

	<u>2024</u>	<u>2023</u>
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 8,279,890	\$ 7,413,137
Investments	3,061,683	3,524,691
Contributions receivable	84	39
Other assets	28,298	2,503
Prepaid expenses	33,443	22,145
	<u>\$ 11,403,398</u>	<u>\$ 10,962,515</u>
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Accounts payable and accrued expenses	\$ 89,878	\$ 54,823
Grants payable	3,702,759	3,143,545
	<u>3,792,637</u>	<u>3,198,368</u>
NET ASSETS		
Without donor restrictions		
Unrestricted	3,103,696	3,993,969
Board designated	555,840	-
With donor restrictions	3,951,225	3,770,178
	<u>7,610,761</u>	<u>7,764,147</u>
	<u>\$ 11,403,398</u>	<u>\$ 10,962,515</u>

*The accompanying notes are an
integral part of these consolidated financial statements*

OPEN MEDICINE FOUNDATION**(A NON-PROFIT CORPORATION)****CONSOLIDATED STATEMENTS OF ACTIVITIES****YEAR ENDED DECEMBER 31, 2024****(WITH SUMMARIZED COMPARATIVE TOTALS FOR DECEMBER 31, 2023)**

	2024			2023
	Without	With Donor		Summarized
	Donor	Restrictions	Total	Total
	Restrictions	Restrictions	Total	Total
REVENUE AND SUPPORT				
Contributions	\$ 2,625,400	\$ 1,586,667	\$ 4,212,067	\$ 2,934,701
Grants	312,956	1,019,226	1,332,182	5,024,285
Other income (loss)	51,940	-	51,940	(25,529)
Interest and dividend income	326,893	-	326,893	132,682
Gain on investments	38,625	-	38,625	73,287
Grant revenue from employee retention credits	-	-	-	187,710
Net assets released from restrictions	2,424,846	(2,424,846)	-	-
	<u>5,780,660</u>	<u>181,047</u>	<u>5,961,707</u>	<u>8,327,136</u>
FUNCTIONAL EXPENSES				
Program services	4,960,951	-	4,960,951	6,427,488
Supporting services	251,145	-	251,145	260,927
Fundraising	590,263	-	590,263	602,621
	<u>5,802,359</u>	<u>-</u>	<u>5,802,359</u>	<u>7,291,036</u>
OTHER ITEMS				
Foreign currency translation gain (loss)	<u>(312,734)</u>	<u>-</u>	<u>(312,734)</u>	<u>42,147</u>
CHANGE IN NET ASSETS	<u>(334,433)</u>	<u>181,047</u>	<u>(153,386)</u>	<u>1,078,247</u>
NET ASSETS, beginning of year	<u>3,993,969</u>	<u>3,770,178</u>	<u>7,764,147</u>	<u>6,685,900</u>
NET ASSETS, end of year	<u>\$ 3,659,536</u>	<u>\$ 3,951,225</u>	<u>\$ 7,610,761</u>	<u>\$ 7,764,147</u>

*The accompanying notes are an
integral part of these consolidated financial statements*

OPEN MEDICINE FOUNDATION**(A NON-PROFIT CORPORATION)****CONSOLIDATED STATEMENTS OF FUNCTIONAL EXPENSES****YEAR ENDED DECEMBER 31, 2024****(WITH SUMMARIZED COMPARATIVE TOTALS FOR DECEMBER 31, 2023)**

	2024				2023
	Program Services	Supporting Services	Fundraising	Total	Summarized Total
Salaries and wages	\$ 820,169	\$ 166,200	\$ 377,800	\$ 1,364,169	\$ 1,007,327
Payroll taxes	43,312	10,672	24,263	78,247	60,537
Employee benefits	41,221	8,881	20,189	70,291	21,312
Total personnel expenses	904,702	185,753	422,252	1,512,707	1,089,176
Program and research grants	3,774,016	-	-	3,774,016	5,594,581
Professional services	129,888	32,126	5,150	167,164	348,507
Marketing and communications	58,276	-	58,275	116,551	61,766
Travel, meetings and conferences	69,706	-	3,558	73,264	67,279
Merchant fees	-	-	59,403	59,403	36,093
Information technology	17,197	11,464	28,661	57,322	46,481
General administration	2,382	10,140	12,964	25,486	25,851
Insurance	-	11,262	-	11,262	8,542
Fundraising	-	-	-	-	6,125
Website	2,775	-	-	2,775	4,927
In-kind labor	2,009	-	-	2,009	1,508
Taxes and licenses	-	400	-	400	200
	<u>\$4,960,951</u>	<u>\$ 251,145</u>	<u>\$ 590,263</u>	<u>\$ 5,802,359</u>	<u>\$ 7,291,036</u>

*The accompanying notes are an
integral part of these consolidated financial statements*

OPEN MEDICINE FOUNDATION**(A NON-PROFIT CORPORATION)****CONSOLIDATED STATEMENTS OF CASH FLOWS****YEAR ENDED DECEMBER 31, 2024****(WITH SUMMARIZED COMPARATIVE TOTALS FOR DECEMBER 31, 2023)**

	<u>2024</u>	<u>2023</u>
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ (153,386)	\$ 1,078,247
Adjustments to reconcile change in net assets to net cash from operating activities:		
Contributed investments	-	(294,852)
Gain on investments	(38,625)	(73,287)
Changes in operating assets and liabilities:		
Contributions receivable and other assets	(25,840)	1,331,133
Prepaid expenses	(11,298)	(20,763)
Accounts payable and accrued expenses	35,055	8,950
Grants payable	<u>559,214</u>	<u>(635,152)</u>
Net cash flows from operating activities	<u>365,120</u>	<u>1,394,276</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of investments	(2,101,731)	(1,850,000)
Interest and dividends reinvested	(168,341)	(42,408)
Proceeds from sale of investments	729,963	-
Withdrawals of investments	<u>2,041,742</u>	<u>228,106</u>
Net cash flows from investing activities	<u>501,633</u>	<u>(1,664,302)</u>
Net change cash and cash equivalents	866,753	(270,026)
Cash and cash equivalents, beginning of year	<u>7,413,137</u>	<u>7,683,163</u>
Cash and cash equivalents, end of year	<u>\$ 8,279,890</u>	<u>\$ 7,413,137</u>

The accompanying notes are an integral part of these consolidated financial statements

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 1 - ORGANIZATION

Open Medicine Foundation, Inc. (the “Foundation,” the “Organization,” a non-profit corporation) was founded in 2012 to fund collaborative medical research and medical education for multi system chronic complex diseases. Its four primary goals are to: 1) frame clear disease mechanisms and models; 2) to find effective treatments and diagnostic markers; 3) increase accurate diagnoses; and 4) ensure access to quality care.

The Organization supports research and clinical trials through six collaborative research centers globally and medical education through one medical education resource center (in partnership with the Bateman Horne Center), and by bringing together a community of “thought leaders,” patients, clinicians and researchers for targeted initiatives. Open Medicine Foundation is currently focused on researching Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (“ME/CFS”), post-infectious Lyme disease, and Long COVID, in hopes of also revealing answers to other multi system chronic complex diseases that share similar symptoms.

The Organization raises funds through three separate entities: Open Medicine Foundation Inc. (OMF), Open Medicine Foundation Canada (OMFCA), and Open Medicine Foundation Australia Limited (OMFAL). All donations received are from private donors - individuals, families, other foundations, etc. OMF receives donations from donors globally and is able to fund research via any of the six collaborative research centers. OMF Canada receives donations from Canadian donors, and is able to fund research, clinical trials, and medical education in Canada and via the OMF Supported Collaborations globally. OMF Australia Limited receives donations from Australia resident donors and a handful of US donors. Any funds received through OMFAL remain in Australia to fund the Melbourne ME/CFS Collaboration.

Each entity is overseen by a Foundation Board and its research is also driven by its Scientific Advisory Board. OMF is also the sole member of the other two entities. OMF provides all back office support and administration to the other two entities. OMF and OMFAL have a formal Services Agreement in place, and an Intermediary Agreement is being finalized for OMF and OMFCA.

Principles of Consolidation - The accompanying consolidated financial statements include the accounts of the Foundation, the Canadian Corporation and the Australian Limited Entity (collectively, the “Organization”). Both the Canadian Corporation and the Australian Limited Entity share two board members and the dependency on the Foundation for its back office and administrative function. The Australian Limited Entity is consolidated on a basis of ownership as it is a 100% owned subsidiary of the Foundation. Inter-company balances and transactions, if any, have been eliminated in consolidation.

*The accompanying notes are an
integral part of these consolidated financial statements*

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 1 - ORGANIZATION, Continued

Funding - The Organization is funded primarily through foundation grants, corporate grants, and private individual donations.

Liquidity and availability of resources - The following reflects the Organization's financial assets as of December 31, 2024, reduced by amounts not available for general use within one year of the consolidated statement of financial position date because of donor restrictions and internal designations:

Cash and cash equivalents	\$ 8,279,890
Investments	3,061,683
Contributions receivable	84
Other assets	<u>28,298</u>
Total financial assets	11,369,955
Board designated net assets	(555,840)
Net assets with donor restrictions	<u>(3,951,225)</u>
Financial assets available to meet cash needs for general expenditures within one year	<u><u>\$ 6,862,890</u></u>

The liquid financial assets of the Organization exceeds its goal of maintaining financial assets on hand for at least twelve months. The Organization has financial assets on hand to meet at least fourteen months of normal operating expenses, which, on average, totals approximately \$484,000 per month given full programmatic expenditures. The Organization plans to spend the available funds for the intended purpose of its philanthropic mission as soon as able.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation - The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. Net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets of the Organization and changes therein are classified and reported as follows:

Net assets without donor restrictions - Net assets available for use in general operations and not subject to donor or certain grantor restrictions.

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Net assets with donor restrictions - Net assets with donor restrictions are assets subject to donor or grantor-imposed restrictions, some of which are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor, while others are perpetual in nature, where the donor stipulates the resources be maintained in perpetuity.

Revenues are reported as increases in net assets without donor restrictions unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Expirations of net assets with donor restrictions are reported as reclassifications between the applicable classes of net assets.

Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Contributions and pledges - Contributions and pledges are recognized at fair value when the donor makes an unconditional transfer of cash or other assets, as well as unconditional promise to give to the Organization. Contributions and pledges that are restricted by the donor are recognized when the conditions on which they depend have been substantially met and reported as increases in net assets without donor restrictions if the restrictions expire in the fiscal year in which the contributions are recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions.

Contributions of services are recognized in the consolidated financial statements (as in-kind revenue and a corresponding in-kind expense) if the services enhance or create non-financial assets or require specialized skills and are provided by individuals possessing those skills and would typically need to be purchased if not provided by donation. During the year ended December 31, 2024, several volunteers who perform services for the Organization have contributed significant amounts of time to the Organization. A dollar valuation of their efforts is not reflected in the consolidated financial statements since it does not meet the criteria for recognition.

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

The President/CEO and certain other staff members of the Organization contribute office space to the Organization. As the value of the contributed rent could not be estimated, no amount for the contributed rent was recorded on the accompanying consolidated financial statements.

Fair value of financial instruments - Financial instruments primarily consist of investments, accounts receivable, and contributions and grants receivable. The Organization estimates that the fair value of its financial instruments at December 31, 2024 do not differ materially from its aggregate carrying value recorded in the accompanying consolidated statement of financial position. Considerable judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, the estimates are not necessarily indicative of the amounts that the Organization could realize in a current market exchange.

Fair value measurements - The Organization defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Organization measures fair value under a framework that provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements), moderate priority to valuations based on observable inputs, such as market prices of similar assets and liabilities (level 2), and the lowest priority to unobservable inputs (level 3).

Cash and cash equivalents - For the purpose of reporting cash flows, cash and cash equivalents include operating cash held in banks. The Organization maintains its cash balances in several financial institutions, which at times may exceed federally insured limits. However, as part of its regular risk management strategies, the Organization assesses its holdings at least quarterly to ensure that all cash is held at financially stable and highly rated institutions, and assets are managed in ways to limit its risks and exposures.

Investments - Investments are reported at fair value as determined by either quoted market prices in an active market or observable inputs. The Organization classifies its marketable debt securities on the date of purchase. The Organization held available-for-sale debt securities which were carried at fair value (Note 4) as of December 31, 2024. Realized gains and losses on dispositions are based on the net proceeds and the adjusted cost basis of the securities using the specific identification method. Unrealized gains and losses are based on the difference between adjusted cost basis and fair value. Gains and losses are reported as a component of change in net assets on the accompanying statements of activities.

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Investments are made according to the investment policies, guidelines and objectives adopted by the Board of Directors. These guidelines provide for investments in equities, fixed income and other securities with performance measured against appropriate indices. Market values of such investments and credit ratings of bond issues are routinely reviewed by the Board of Directors.

Contributions receivable - Contributions receivable represent contributions to the Organization by private donors that are collectible after the year-end. It is the policy of management to review outstanding contributions receivables at year end, as well as any historical bad debt write-offs, to establish an allowance for uncollectable amounts. Collection losses related to contributions receivable have historically been minimal. As such, no allowance for uncollectible accounts was recorded.

Grants payable - Grants payable as of December 31, 2024, were funds committed by the Organization to other entities for the advancement of research, medical education, and to increase awareness of ME/CFS and other multi-system chronic complex diseases.

Grant research - Grant research represents funds granted to clinical and academic research facilities for direct research into multi-system chronic complex diseases.

Board designated funds - Board designated fund represents funds that are to be used by the Organization for future expenditures pertaining to specific research. These funds are derived from operating cash flows and are not donor-restricted. The use of these accounts require authorization from the Board of Directors. As of December 31, 2024, the Organization has assets of \$555,840 board designated for a BioQuest Biomarker study.

Foreign currency translation - The U.S. Dollar is the functional currency for the Organization. Transactions in currencies other than U.S. Dollars are translated into dollars at the approximate rates of exchange in effect during the time of the transaction.

Current assets, current liabilities, and net assets with donor restrictions denominated in non-U.S. currency are translated into dollars at the exchange rate in effect at the date of the Statements of Financial Position.

Currency gains and losses from translation are recorded under Other Items in the accompanying consolidated statement of activities.

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Expense allocation - The costs of providing various programs and other activities have been summarized on a functional basis in the consolidated statement of activities and in the consolidated statement of functional expenses. During the year, costs are categorized into separate groupings as either direct or indirect. Indirect or shared costs are allocated among program and support activities by the method that best measures the relative degree of benefit.

Program services - Expenses include costs that primarily relate to research projects and other costs supporting medical research.

Supporting services - Expenses include costs that primarily relate to management and general administration

Fundraising - Expenses include costs that primarily relate to fundraising activities to obtain grants and generate revenue through contributions.

Income taxes - The Foundation is a qualified non-profit organization under Section 501(c) (3) of the Internal Revenue Code ("IRC") and is not classified as a private foundation. Non-profit organizations are not generally liable for taxes on income; therefore, no provision is made for such taxes for the Organization in the consolidated financial statements. The Organization had no unrelated business income during the year ended December 31, 2024.

The Canadian Corporation is exempt from income tax as a registered charity under the Income Tax Act of Canada.

The Australian Limited Entity is also exempt from income tax as a Charity registered with the Australian Charities and Not-for-Profit Commission and endorsed by the Australian Taxation Office for charity tax concessions under Income Tax Act of 1997 of Australia.

The Organization recognizes the impact of tax positions in the consolidated financial statements if that position is more likely than not of being sustained in an audit, based on the technical merits of the position. To date, the Organization has not recorded any uncertain tax positions. During the year ended December 31, 2024, the Organization did not recognize any amount in potential interest and penalties associated with uncertain tax positions. As of December 31, 2024, all federal tax returns since the 2021 tax year and state tax returns since the 2020 tax year of Foundation are still subject to adjustment upon audit. No tax returns are currently being examined by taxing authorities.

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Risks and uncertainties - Certain services of the Organization are governed by grant agreements with foundations. Failure to fulfill grant terms could result in the return of funds to grantors. Although it is a possibility, the Organization considers the contingency remote since, by accepting the grant and its terms, the Organization acknowledges the requirements of the grantor at the time of award.

The Organization also invests in various certificates of deposits and government marketable debt securities. The marketable debt securities are exposed to various risks, such as interest rate, market, and credit risks. Market risks include global events which could impact the value of the marketable debt securities, such as a pandemic, global inflationary environments, or international conflict.

Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of the marketable debt securities will occur in the near term and that such changes could materially affect balances and accounts reported by the Organization.

Comparative totals - The consolidated financial statements include certain prior year summarized comparative information in total, but not by net asset class. The notes to the consolidated financial statements do not contain the financial information on a comparative basis. Such summarized information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the Organization's financial statements for the year ended December 31, 2023, from which the summarized information was derived.

Reclassifications - Certain amounts previously presented in previous financial statements have been reclassified to conform to the current presentation of the accompanying consolidated financial statements to maintain consistency between reporting periods presented.

Subsequent events - Subsequent events have been evaluated by the Organization through May 7, 2025, which is the date these consolidated financial statements were able to be issued, and no subsequent events have arisen that would require disclosure.

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 3 - NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions, net of foreign currency transaction gain, for the following purposes or periods at December 31, 2024 consist of the following:

	January 1, 2024	Additions	Releases	December 31, 2024
With Donor Restrictions - OMF				
<u>General Research Funds</u>				
General Research Programs	\$ 30,100	\$ 32,050	\$ -	\$ 62,150
ME/CFS Research	24,784	128,680	(120,001)	33,463
BioQuest BioMarker Study	-	515,330	-	515,330
Lyme Research	1,800	325	-	2,125
Covid-19 Research	35,907	28,000	(25,000)	38,907
<u>Harvard Collaborative Research Center</u>				
Harvard CRC General Funds	36,790	498	-	37,288
PEM Muscle Biopsy	831	-	-	831
<u>Melbourne Collaborative Research Center</u>				
Melbourne CRC General Funds	18,182	-	-	18,182
Nitrogen Metabolism Studies	361,625	-	(2,064)	359,561
Personalized Treatment Trial	16,015	61,000	(74,818)	2,197
<u>Montreal Collaborative Research Center</u>				
Montreal CRC General Funds	208	108	-	316
<u>Stanford Collaborative Research Center</u>				
Stanford CRC General Funds	348,222	7,299	(151,383)	204,138
Family Omics Study	-	54,605	(36,000)	18,605
Diagnostics Development (Nanoneedle)	2,873	-	-	2,873
Itaconate Project	687	67	(710)	44
Whitney Dafoe	-	42,895	(42,895)	-
Viral Risk Factors in ME/CFS	26,221	-	-	26,221
<u>Uppsala Collaborative Research Center</u>				
Uppsala CRC General Funds	242,142	52,988	(2,000)	293,130
<u>Balvi Supported Patient Led Research Fund</u>				
Multi-Omics/MOSAICS	9,600	-	-	9,600
Network Analysis	5,650	-	(5,640)	10
Microbial Metabolites	10,400	-	(2,400)	8,000
Altered T-Cell Responses	4,800	-	-	4,800
Pathophysiology of PEM	-	-	-	-
Sleep Study for Long COVID	496,020	-	(487,620)	8,400
Monoclonal Antibody Trial	18,400	-	(1,000)	17,400
Foraminal Stenosis	15,200	-	-	15,200
<u>Other Programs</u>				
Medical Education	89,249	37,923	(79,844)	47,328
Medical Education International	-	65	-	65
Clinician Coalition & Symposiums	152,011	-	(140,600)	11,411
Bateman Horne Center Medical Education	675	305	(980)	-
<u>Clinical Trials</u>				
LIFT Trial	292,774	600,600	(893,374)	-
	<u>2,241,166</u>	<u>1,562,738</u>	<u>(2,066,329)</u>	<u>1,737,575</u>

OPEN MEDICINE FOUNDATION

(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2024

NOTE 3 - NET ASSETS WITH DONOR RESTRICTIONS, Continued

	January 1, 2024	Additions	Releases	December 31, 2024
With Donor Restrictions - OMF CANADA				
<u>General Research Funds - Canada</u>				
ME/CFS Research	381,730	2,581	-	384,311
Medical education	-	76	-	76
BioQuest BioMarker Study	-	1,220	-	1,220
Clinical Trials	100,366	-	-	100,366
<u>Harvard Collaborative Research Center - Canada</u>				
iCPET Multi-Omic	49,248	-	-	49,248
<u>Montreal Collaborative Research Center- Canada</u>				
Montreal CRC General Funds	9,593	94,817	-	104,410
REMEDIAL	-	358,517	(358,517)	-
RASPBERRY-ME	306	115	-	421
MEDUSA	-	243,180	-	243,180
Fibromyalgia Research	115	-	-	115
<u>Stanford Collaborative Research Center - Canada</u>				
Stanford CRC General Funds	6,484	-	-	6,484
<u>Uppsala Collaborative Research Center - Canada</u>				
Deep Assessment of Neuroinflammation	568,887	-	-	568,887
	<u>1,116,729</u>	<u>700,506</u>	<u>(358,517)</u>	<u>1,458,718</u>
With Donor Restrictions - OMF AUSTRALIA				
<u>General Research Funds - Melbourne</u>				
ME/CFS Research	20,445	-	-	20,445
Personalized Treatment Trial	374,825	342,649	-	717,474
SPOT-ME Project	17,013	-	-	17,013
	<u>412,283</u>	<u>342,649</u>	<u>-</u>	<u>754,932</u>
Total Net Assets With Donor Restrictions	<u>\$ 3,770,178</u>	<u>\$ 2,605,893</u>	<u>\$ (2,424,846)</u>	<u>\$ 3,951,225</u>

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 4 - FAIR VALUE MEASUREMENTS AND INVESTMENTS

Fair value is based on observable inputs (readily obtainable data from independent sources) and unobservable inputs (internally derived and reflecting the Organization's market assumptions). Inputs are classified into the following hierarchy based on the level of judgment used to measure their fair value:

Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 - Inputs other than Level 1 inputs that are either directly or indirectly observable.

Level 3 - Unobservable inputs using estimates and assumptions developed by management.

Marketable debt securities consist of brokered certificates of deposit and U.S. treasury bills, which are valued at the closing price, reported in the active market in which the individual security is traded.

The following is a description of the valuation methodologies used for the investments measured at fair value, including the general classification of such instruments pursuant to the valuation hierarchy.

Brokered certificates of deposit - Certificates of deposit (CDs) are time deposits offered by banks and purchased through the Organization's broker. CDs are FDIC insured and traded in the secondary market. All CDs have maturities of six to twelve months from their origination dates with interest rates ranging from 4.20% to 5.40%. All CDs were reported as Level 1 under the valuation hierarchy. CDs had a cost basis of \$1,314,100 and unrealized gains of \$2,131 as of December 31, 2024. The unrealized gains for the year ended December 31, 2024 were recorded within gain on investments for the year ended December 31, 2024 in the accompanying consolidated statement of activities.

U.S. government securities - The U.S. treasury bills are reported at fair value based on Level 1 inputs. The U.S. treasury bills mature on various dates between January 2025 and September 2027. The U.S. treasury bills had a fair market value of \$1,745,452 as of December 31, 2024. The unrealized gains for the year ended December 31, 2024 were recorded within gain on investments for the year ended December 31, 2024 in the accompanying consolidated statement of activities.

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024

NOTE 4 - FAIR VALUE MEASUREMENTS AND INVESTMENTS, Continued

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Organization believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following table provides the fair value for each major category of assets measured at fair value at December 31, 2024:

Certificates of deposit	\$ 1,316,231
U. S. government securities	<u>1,745,452</u>
	<u><u>\$ 3,061,683</u></u>

NOTE 5 - EMPLOYEE BENEFIT PLAN

The Organization provides a 403(b) retirement savings plan (the “Plan”), which covers all eligible employees of the Organization. Participants may defer up to the maximum annual contributions under applicable tax regulations. During the year ended, December 31, 2024, the Organization did not make any matching or discretionary contributions to the Plan.

SUPPLEMENTARY SCHEDULES

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

CONSOLIDATING SCHEDULE OF FINANCIAL POSITION
DECEMBER 31, 2024

	<u>OMF</u>	<u>OMF Canada</u>	<u>OMF Australia</u>	<u>Total</u>	<u>Eliminations</u>	<u>Consolidated</u>
ASSETS						
CURRENT ASSETS						
Cash and cash equivalents	\$ 4,696,190	\$ 2,986,621	\$ 597,079	\$ 8,279,890	\$ -	\$ 8,279,890
Investments	2,439,495	-	622,188	3,061,683	-	3,061,683
Contributions receivable	-	-	84	84	-	84
Other assets	26,886	1,412	-	28,298	-	28,298
Due from related parties	118,442	-	17,113	135,555	(135,555)	-
Prepaid expenses	<u>30,439</u>	<u>3,004</u>	<u>-</u>	<u>33,443</u>	<u>-</u>	<u>33,443</u>
	<u>\$ 7,311,452</u>	<u>\$ 2,991,037</u>	<u>\$ 1,236,464</u>	<u>\$ 11,538,953</u>	<u>\$ (135,555)</u>	<u>\$11,403,398</u>
LIABILITIES AND NET ASSETS						
CURRENT LIABILITIES						
Accounts payable and accrued expenses	\$ 69,818	\$ 7,576	\$ 12,484	\$ 89,878	\$ -	\$ 89,878
Due to related parties	17,113	69,478	48,964	135,555	(135,555)	-
Grants payable	<u>3,702,759</u>	<u>-</u>	<u>-</u>	<u>3,702,759</u>	<u>-</u>	<u>3,702,759</u>
	<u>3,789,690</u>	<u>77,054</u>	<u>61,448</u>	<u>3,928,192</u>	<u>(135,555)</u>	<u>3,792,637</u>
NET ASSETS						
Without donor restrictions						
Unrestricted	1,784,187	899,425	420,084	3,103,696	-	3,103,696
Baord designated	-	555,840	-	555,840	-	555,840
With donor restrictions	<u>1,737,575</u>	<u>1,458,718</u>	<u>754,932</u>	<u>3,951,225</u>	<u>-</u>	<u>3,951,225</u>
	<u>3,521,762</u>	<u>2,913,983</u>	<u>1,175,016</u>	<u>7,610,761</u>	<u>-</u>	<u>7,610,761</u>
	<u>\$ 7,311,452</u>	<u>\$ 2,991,037</u>	<u>\$ 1,236,464</u>	<u>\$ 11,538,953</u>	<u>\$ (135,555)</u>	<u>\$11,403,398</u>

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

CONSOLIDATING SCHEDULE OF ACTIVITIES
DECEMBER 31, 2024

	OMF			OMF Canada			OMF Australia				
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total	Eliminations	Grand Total
REVENUE AND SUPPORT											
Contributions	\$ 1,918,421	\$ 886,161	\$ 2,804,582	\$ 583,449	\$ 700,506	\$ 1,283,955	\$ 123,530	\$ -	\$ 123,530	\$ -	\$ 4,212,067
Grants	308,937	676,577	985,514	4,019	-	4,019	-	342,649	342,649	-	1,332,182
Other income (loss)	207,937	-	207,937	(1,738)	-	(1,738)	108,659	-	108,659	(262,918)	51,940
Interest and dividend income	232,926	-	232,926	72,247	-	72,247	21,720	-	21,720	-	326,893
Gain on investments	38,625	-	38,625	-	-	-	-	-	-	-	38,625
Net assets released from restrictions	2,066,329	(2,066,329)	-	358,517	(358,517)	-	-	-	-	-	-
	<u>4,773,175</u>	<u>(503,591)</u>	<u>4,269,584</u>	<u>1,016,494</u>	<u>341,989</u>	<u>1,358,483</u>	<u>253,909</u>	<u>342,649</u>	<u>596,558</u>	<u>(262,918)</u>	<u>5,961,707</u>
EXPENSES											
Program services	4,550,971	-	4,550,971	486,580	-	486,580	186,318	-	186,318	(262,918)	4,960,951
Supporting services	241,687	-	241,687	9,458	-	9,458	-	-	-	-	251,145
Fundraising	584,560	-	584,560	3,281	-	3,281	2,422	-	2,422	-	590,263
	<u>5,377,218</u>	<u>-</u>	<u>5,377,218</u>	<u>499,319</u>	<u>-</u>	<u>499,319</u>	<u>188,740</u>	<u>-</u>	<u>188,740</u>	<u>(262,918)</u>	<u>5,802,359</u>
OTHER ITEMS											
Foreign currency translation gain (loss)	-	-	-	(212,811)	-	(212,811)	(99,923)	-	(99,923)	-	(312,734)
CHANGE IN NET ASSETS	(604,043)	(503,591)	(1,107,634)	304,364	341,989	646,353	(34,754)	342,649	307,895	-	(153,386)
NET ASSETS, beginning of year	<u>2,388,230</u>	<u>2,241,166</u>	<u>4,629,396</u>	<u>1,150,901</u>	<u>1,116,729</u>	<u>2,267,630</u>	<u>454,838</u>	<u>412,283</u>	<u>867,121</u>	<u>-</u>	<u>7,764,147</u>
NET ASSETS, end of year	<u>\$ 1,784,187</u>	<u>\$ 1,737,575</u>	<u>\$ 3,521,762</u>	<u>\$ 1,455,265</u>	<u>\$ 1,458,718</u>	<u>\$ 2,913,983</u>	<u>\$ 420,084</u>	<u>\$ 754,932</u>	<u>\$ 1,175,016</u>	<u>\$ -</u>	<u>\$ 7,610,761</u>

OPEN MEDICINE FOUNDATION
(A NON-PROFIT CORPORATION)

CONSOLIDATING SCHEDULE OF FUNCTIONAL EXPENSES
DECEMBER 31, 2024

	OMF				OMF Canada				OMF Australia					
	Program	Supporting			Program	Supporting			Program	Supporting			Grand	
	Services	Services	Fundraising	Total	Services	Services	Fundraising	Total	Services	Services	Fundraising	Total	Eliminations	Total
Salaries and wages	\$ 783,828	\$ 166,200	\$ 377,800	\$ 1,327,828	\$ -	\$ -	\$ -	\$ -	\$ 145,752	\$ -	\$ -	\$ 145,752	\$ (109,411)	\$ 1,364,169
Payroll taxes	43,312	10,672	24,263	78,247	-	-	-	-	-	-	-	-	-	78,247
Employee benefits	36,041	8,881	20,189	65,111	-	-	-	-	5,180	-	-	5,180	-	70,291
Total personnel expenses	863,181	185,753	422,252	1,471,186	-	-	-	-	150,932	-	-	150,932	(109,411)	1,512,707
Program and research grants	3,429,458	-	-	3,429,458	467,170	-	-	467,170	6,500	-	-	6,500	(129,112)	3,774,016
Professional services	110,478	32,126	5,150	147,754	19,410	-	-	19,410	-	-	-	-	-	167,164
Marketing and communications	58,276	-	58,275	116,551	-	-	-	-	-	-	-	-	-	116,551
Travel, meetings and conferences	67,597	-	3,558	71,155	-	-	-	-	2,109	-	-	2,109	-	73,264
Merchant fees	-	-	53,700	53,700	-	-	3,281	3,281	-	-	2,422	2,422	-	59,403
Information technology	17,197	11,464	28,661	57,322	-	-	-	-	-	-	-	-	-	57,322
Contract service expenses paid to OMF Foundation by OMF AUS	-	-	-	-	-	-	-	-	24,395	-	-	24,395	(24,395)	-
General administration	-	682	12,964	13,646	-	9,458	-	9,458	2,382	-	-	2,382	-	25,486
Insurance	-	11,262	-	11,262	-	-	-	-	-	-	-	-	-	11,262
Website	2,775	-	-	2,775	-	-	-	-	-	-	-	-	-	2,775
In-kind labor	2,009	-	-	2,009	-	-	-	-	-	-	-	-	-	2,009
Taxes and licenses	-	400	-	400	-	-	-	-	-	-	-	-	-	400
	<u>\$4,550,971</u>	<u>\$ 241,687</u>	<u>\$ 584,560</u>	<u>\$ 5,377,218</u>	<u>\$ 486,580</u>	<u>\$ 9,458</u>	<u>\$ 3,281</u>	<u>\$ 499,319</u>	<u>\$ 186,318</u>	<u>\$ -</u>	<u>\$ 2,422</u>	<u>\$ 188,740</u>	<u>\$ (262,918)</u>	<u>\$ 5,802,359</u>